{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/heart-failure-chronic/how-up-to-date-is-this-topic/changes/","result":{"pageContext":{"chapter":{"id":"fd5e8a95-3e97-5ec2-98ae-5a10c2373213","slug":"changes","fullItemName":"Changes","depth":2,"htmlHeader":"<!-- begin field f4135623-f5ed-4832-a52e-897a2ba36317 --><h2>Changes</h2><!-- end field f4135623-f5ed-4832-a52e-897a2ba36317 -->","summary":null,"htmlStringContent":"<!-- begin item bf9c0e6b-5b82-42f0-962f-1cd447fd081f --><!-- begin field 32637d32-e470-41a3-a4eb-bd4801dea68f --><p><strong>May 2020</strong> – minor update. Prescribing information has been added in response to the National Institute for Health and Care Excellence (NICE)<em> COVID-19 rapid evidence summary: angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs) in people with or at risk of COVID-19</em> to reflect the advice during the COVID-19 pandemic.</p><p><strong>August 2019 </strong>— minor update. The topic has been updated in line with the National Institute for Health and Care Excellence (NICE) guideline <em>Chronic heart failure in adults: diagnosis and management </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/heart-failure-chronic/references/\">NICE, 2018</a>].</p><p><strong>January 2017 </strong>— reviewed. The topic has been updated to include recommendations from the Scottish Intercollegiate Guidelines Network (SIGN) guideline <em>Management of chronic heart failure </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/heart-failure-chronic/references/\">SIGN, 2016</a>]<em>.</em></p><!-- end field 32637d32-e470-41a3-a4eb-bd4801dea68f --><!-- end item bf9c0e6b-5b82-42f0-962f-1cd447fd081f -->","topic":{"id":"3a35207f-30ea-5eca-bfcf-dff091a73359","topicId":"fdc42e20-2c4b-45ed-9093-6c2d4bde6e4d","topicName":"Heart failure - chronic","slug":"heart-failure-chronic","lastRevised":"Last revised in January 2017","chapters":[{"id":"77c928c1-46d0-58c1-ba79-6015f89bc48a","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"f0aa9151-9d10-566e-85ec-6ccefed25f20","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"c036596d-f29d-5486-822a-b46af76451d7","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"fd5e8a95-3e97-5ec2-98ae-5a10c2373213","slug":"changes","fullItemName":"Changes"},{"id":"4c4375f1-a348-5b99-b895-f04a15c64791","slug":"update","fullItemName":"Update"}]},{"id":"7472c037-35d4-5fd2-bba6-dfd891ade816","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"cde936d1-3945-5bc6-8c22-9106d78cf77c","slug":"goals","fullItemName":"Goals"},{"id":"bfa0b8d3-fac0-500e-a762-f719dc619f1b","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"5d2cf55e-1ae2-5000-9c94-e9c86d26a824","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"c8203a8a-fc22-5378-b33b-34ddf818dea5","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"4b5e4f72-1a3e-531c-be82-a1919603c934","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"c206f1b2-7616-587d-b3bf-b65ba5b5adb4","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"ab1d2b81-1f2b-55e5-abf0-c14e4ae4a78d","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"cb83ac3c-e97e-5cab-acca-5abebc7bd6b1","slug":"definition","fullItemName":"Definition"},{"id":"66c995b7-504c-5510-9e77-1a9b27ee7dca","slug":"causes","fullItemName":"Causes"},{"id":"88dbdf7b-53b7-5952-97b9-2312c0a2ce63","slug":"prevalence","fullItemName":"Prevalence"},{"id":"a0b16521-d808-5dfd-89dc-64fc6ae7f6ce","slug":"prognosis","fullItemName":"Prognosis"},{"id":"262fb896-526d-594f-8142-98c291781249","slug":"complications","fullItemName":"Complications"}]},{"id":"72804751-fb0c-5a96-85b5-982feb950f16","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"8b798e41-3fbe-5027-9365-da41e1c98e93","slug":"when-to-suspect","fullItemName":"When to suspect"},{"id":"e6498250-f313-5ea2-a1e8-2d0342823c39","slug":"how-to-manage-suspected","fullItemName":"How to manage suspected"},{"id":"74e553b4-7cb8-52a6-a573-8715f63a2ba8","slug":"how-to-assess","fullItemName":"How to assess"},{"id":"53bf7ae0-a1d0-5fae-9d3b-57cbc6f03bb8","slug":"what-else-could-it-be","fullItemName":"What else could it be"}]},{"id":"38c5edc8-6b4a-5e71-bb70-cf0a09389ae0","fullItemName":"Management","slug":"management","subChapters":[{"id":"97a0eca4-a290-588b-a16a-bc95b93cd893","slug":"confirmed-heart-failure-with-reduced-ejection-fraction","fullItemName":"Scenario: Confirmed heart failure with reduced ejection fraction"},{"id":"34ff8094-815a-55b7-9edd-49f3ac636471","slug":"confirmed-heart-failure-with-preserved-ejection-fraction","fullItemName":"Scenario: Confirmed heart failure with preserved ejection fraction"},{"id":"28fde475-ef24-59d3-9171-a8d59a3fb149","slug":"end-stage-heart-failure","fullItemName":"Scenario: End-stage heart failure"},{"id":"c587255a-a47e-57a1-bc4d-967753c38d11","slug":"information-advice-follow-up-referral","fullItemName":"Scenario: Information and advice, follow-up, and referral"}]},{"id":"e82d6013-cb43-59d5-9e2e-0af05276fb9d","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"8fd96acc-3fa6-528b-9351-49db836228b1","slug":"managing-aiiras","fullItemName":"Managing AIIRAs"},{"id":"06c9d276-e5ea-5a0b-9ff4-343f10034763","slug":"managing-ace-inhibitors","fullItemName":"Managing ACE-inhibitors"},{"id":"df53e9a8-07f8-5d37-94cf-78e99d4c8216","slug":"managing-beta-blockers","fullItemName":"Managing beta-blockers"},{"id":"faad170c-d1ee-59ad-9847-f7afdda6d9b9","slug":"managing-diuretics","fullItemName":"Managing diuretics"},{"id":"a3ea6beb-7ee3-586c-9985-47c20d804195","slug":"covid-19","fullItemName":"COVID-19"}]},{"id":"7b9c5d56-39f1-53df-b1f9-2dcc5bbb498a","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"df3b6e0c-ca5a-59eb-93e6-4b4370389ed2","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"7a756ff1-7152-5bdd-92ca-7f9e67351dd9","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"f5e1707e-f2a9-54e0-92fa-71beb41e38af","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"691681cc-720f-5242-9fb3-3040860027e7","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"7f39ec24-cb87-5fba-ae6b-6fb2d9538859","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"4afe2b30-f837-53a3-88df-7b1913a54081","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"d4dace55-ef1c-5675-bdbe-180512d549fa","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"c036596d-f29d-5486-822a-b46af76451d7","slug":"how-up-to-date-is-this-topic","fullItemName":"How up-to-date is this topic?"},"subChapters":[{"id":"178e89ad-b70c-5853-a2e0-cd9d8e09205c","slug":"previous-changes","fullItemName":"Previous changes","depth":3,"htmlHeader":"<!-- begin field 59bd5fa8-d99f-4916-9650-274553522495 --><h3>Previous changes</h3><!-- end field 59bd5fa8-d99f-4916-9650-274553522495 -->","summary":null,"htmlStringContent":"<!-- begin item f8b9c159-3df1-44cd-a7be-ce3d306247ab --><!-- begin field d6d5ee63-d07d-437e-8a31-7c6173b430ca --><p><strong>December 2016</strong> — minor update. Information about a possible interaction between ACE inhibitors and mammalian target of rapamycin (mTor) inhibitor therapy, which may increase the risk of angioedema, has been added to this topic ABPI, 2016.</p><p><strong>July to November 2015</strong> — reviewed. A literature search was conducted in November 2015 to identify evidence-based guidelines, UK policy, systematic reviews, and key randomized controlled trials published since the last revision of this topic. Text changes include alterations to the classification of heart failure as 'heart failure with reduced ejection fraction' and 'heart failure with preserved ejection fraction'.</p><p><strong>May 2015</strong> — minor updates:</p><ul><li>The Medicines and Healthcare products Regulatory Agency (MHRA) warning regarding the concomitant use of renin-angiotensin hormone system (RAS) drugs has been clarified.</li><li>Information about the increased risk of hyperkalaemia with concurrent use of spironolactone and nonsteroidal anti-inflammatory drugs has been updated in line with the Summary of Product Characteristics for spironolactone.</li><li>A drug interaction section for spironolactone has been added to the topic.</li></ul><p><strong>December 2014 </strong>— minor updates. Cilazapril preparations have been discontinued and removed from this topic.<br><strong>July 2014 </strong>— two minor updates:</p><ul><li>Text has been incorporated into the topic to reflect guidance from the MHRA that combination use of medicines from different classes of renin-angiotensin system blocking agents is associated with an increased risk of hyperkalaemia, hypotension, and impaired renal function.</li><li>The text has been updated to replace the Liverpool Care Pathway with new standards of care that have been issued by the Leadership Alliance for the Care of Dying People (<a href=\"http://www.nhsiq.nhs.uk/media/2485900/duties_and_responsibilities_of_health_and_care_staff_-_with_prompts_for_practice.pdf\" data-hyperlink-id=\"74fcd554-2c29-40df-b3d1-a9310098331c\">www.nhsiq.nhs.uk (pdf)</a>).</li></ul><p><strong>March 2014 </strong>— minor update. The text on the use of ivabradine in people with heart failure has been updated. Ivabradine is now only contraindicated in people who have acute or unstable heart failure.</p><p><strong>December 2013 </strong>— minor update. Prescribing information has been updated in line with the Summary of Product Characteristics for perindopril.</p><p><strong>July 2013 </strong>— minor update. Links to the DVLA website have been updated.</p><p><strong>June 2013 </strong>— minor update. The 2013 QOF options for local implementation have been added to this topic.</p><p><strong>February 2013 </strong>— minor update. The 2013 QIPP options for local implementation have been added to this topic.</p><p><strong>January 2013 </strong>— minor update. Removed the black triangle status from losartan and valsartan as these drugs no longer have black triangle status. Change to the text regarding the dose of losartan following the publication of the European Society of Cardiology guidelines for Acute and Chronic Heart Failure.</p><p><strong>October 2012 </strong>— minor update. The 2012 QIPP options for local implementation have been added to this topic.</p><p><strong>March 2012 </strong>— minor update. The 2012/2013 QOF indicators have been added to this topic. Issued in April 2012.</p><p><strong>February 2012 </strong>— minor update. Minor typographical error corrected in Prescribing Information. Issued in February 2012.</p><p><strong>January 2012 </strong>— minor update. Added updated information from the manufacturer's Summary of Product Characteristics (SPC) stating that asthenia is a common adverse effect of bisoprolol in people with chronic heart failure. Issued in January 2012.</p><p><strong>July 2011 </strong>— minor update. Included cough as a very rare, but possible adverse effect of candesartan. This information is based on the updated Summary of Product Characteristics for Amias®. Issued in September 2011.</p><p><strong>May 2011 </strong>— minor update. The 2011/2012 QOF indicators and the 2010/2011 QIPP options for local implementation have been added to this topic. Issued in June 2011.</p><p><strong>August to November 2010 </strong>— topic updated. The evidence-base has been reviewed in detail, and recommendations are more clearly justified and transparently linked to the supporting evidence.<br>Updated to reflect the publication of the National Institute for Health and Care Excellence (NICE) guideline <em>Chronic heart failure: national clinical guideline for diagnosis and management in primary and secondary care</em>. The diagnostic and management scenarios as well as evidence sections have been rewritten or updated.</p><!-- end field d6d5ee63-d07d-437e-8a31-7c6173b430ca --><!-- end item f8b9c159-3df1-44cd-a7be-ce3d306247ab -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}